Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over
62 000 new cases occurred in men and women in 2015. The incidence continues to rise …

Despite recent breakthroughs in treatment of advanced thyroid cancers, prognoses remain
poor. Treatment of advanced, progressive disease remains challenging, with limited …

Anaplastic thyroid carcinoma is one of the most aggressive and deadly cancers in humans
and accounts for one to two cases per million persons annually. The rarity of this malignancy …

Increased understanding of disease-specific molecular targets of therapy has led to the
regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of …

Aims Lenvatinib was recently approved for the treatment of radioiodine‐refractory
differentiated thyroid cancer (RR‐DTC). Here, we characterized the pharmacokinetic (PK) …

Anaplastic thyroid carcinoma (ATC) accounts for only 1 to 2% of all thyroid carcinomas, but it
is one of the most lethal neoplasms in humans. To obtain further insights into this” orphan …

Lenvatinib (Lenvima®) is an oral, multi-targeted tyrosine kinase inhibitor (TKI) of vascular
endothelial growth factor (VEGF) receptors 1, 2 and 3, fibroblast growth factor receptors 1, 2 …

Introduction: Patients with progressive, metastatic, RAI-refractory differentiated thyroid
cancer (DTC), as well as patients with advanced medullary (MTC) and anaplastic thyroid …

Background: Historical anaplastic thyroid cancer (ATC) outcomes have been terrible, with a
median survival of only five months and< 20% one-year survival. Improved outcomes are …

Although patients with thyroid cancer generally fare well, there is a subset for which this is
not necessarily true. Progress in understanding the molecular aberrations in thyroid cancer …